• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.

作者信息

Keow Samantha, Abu-Hilal Mohannad

机构信息

Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Division of Dermatology, McMaster University, Hamilton, Ontario, Canada.

出版信息

J Am Acad Dermatol. 2024 Oct;91(4):734-735. doi: 10.1016/j.jaad.2024.05.081. Epub 2024 Jun 9.

DOI:10.1016/j.jaad.2024.05.081
PMID:38857764
Abstract
摘要

相似文献

1
Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study.阿布昔替尼用于从度普利尤单抗和/或曲罗芦单抗转换过来的中度至重度特应性皮炎患者治疗的有效性：一项真实世界回顾性研究。
J Am Acad Dermatol. 2024 Oct;91(4):734-735. doi: 10.1016/j.jaad.2024.05.081. Epub 2024 Jun 9.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.使用曲罗芦单抗治疗长达4年的头颈部特应性皮炎患者的长期疾病控制和最小疾病活动度
Am J Clin Dermatol. 2025 Mar 14. doi: 10.1007/s40257-025-00931-1.
4
Abrocitinib versus dupilumab: Impact on skin barrier function and proteomics in atopic dermatitis.阿布昔替尼与度普利尤单抗对比：对特应性皮炎皮肤屏障功能和蛋白质组学的影响
J Am Acad Dermatol. 2025 Aug;93(2):406-414. doi: 10.1016/j.jaad.2025.04.027. Epub 2025 Apr 15.
5
Effectiveness and safety of age-based dosing of abrocitinib in children and adolescents with moderate to severe atopic dermatitis: A two-center, prospective real-world study in China.阿巴西普按年龄给药治疗中重度特应性皮炎儿童及青少年的有效性和安全性：一项在中国开展的两中心前瞻性真实世界研究。
Medicine (Baltimore). 2025 Apr 18;104(16):e42231. doi: 10.1097/MD.0000000000042231.
6
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.乌帕替尼与度普利尤单抗治疗四个身体部位中重度特应性皮炎的疗效和安全性：来自Heads Up研究的分析
Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30.
7
Systemic treatments for eczema: a network meta-analysis.湿疹的全身治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2.
8
Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE.中重度特应性皮炎患者从度普利尤单抗转换为阿布昔替尼治疗：JADE DARE研究中使用度普利尤单抗治疗后疗效的事后分析
Dermatol Ther (Heidelb). 2025 Feb;15(2):367-380. doi: 10.1007/s13555-024-01320-y. Epub 2025 Feb 4.
9
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis).JAK抑制剂在60岁以上中重度特应性皮炎患者中的疗效和安全性：一项为期52周的多中心、真实世界研究——意大利特应性皮炎研究（IL AD）
Arch Dermatol Res. 2025 May 23;317(1):777. doi: 10.1007/s00403-025-04278-9.
10
Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.在一项实时系统评价和网络荟萃分析中比较特应性皮炎系统免疫调节治疗的二分类疗效结局。
Br J Dermatol. 2024 Jan 23;190(2):184-190. doi: 10.1093/bjd/ljad393.

引用本文的文献

1
Switching from Dupilumab to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Podcast Article.中度至重度特应性皮炎患者从度普利尤单抗转换为阿布昔替尼：一篇播客文章
Dermatol Ther (Heidelb). 2025 Aug 6. doi: 10.1007/s13555-025-01491-2.